<DOC>
	<DOCNO>NCT02672319</DOCNO>
	<brief_summary>Bleeding gastroesophageal varix one major complication cirrhosis . After successful treatment acute bleed episode , patient receive follow-up treatment prevent rebleeding report rebleeding rate 60 % within 1- 2 year . The presence liver cancer and/or portal vein thrombosis associate recurrent variceal bleeding . In study liver cancer patient Hong Kong , 7.9 % patient develop least 1 episode variceal bleed course liver cancer . In patient portal hypertension cirrhosis , current guideline recommend non-selective beta-blocker , endoscopic band ligation esophageal varix initial bleeding , either cyanoacrylate injection variceal obturation transjugular intrahepatic portosystemic shunt gastric varix initial bleeding . However , unclear whether strategy clinical effect patient liver cancer and/or portal vein thrombosis high risk recurrent bleeding . Recently , technique endoscopic ultrasound ( EUS ) guide cyanoacrylate ( glue ) injection variceal obturation describe . In study patient gastric variceal bleeding , EUS guide glue injection coil report achieve hemostasis patient 96 % gastric varix remain obliterated follow-up period . To date , dedicate study evaluate role EUS guide glue injection prevention future bleed patient high risk recurrent variceal bleed liver cancer portal vein thrombosis . The investigator propose study evaluate feasibility safety EUS guide glue injection follow-up variceal treatment patient high risk recurrent variceal bleeding , liver cancer and/or portal vein thrombosis .</brief_summary>
	<brief_title>EUS-guided Glue Injection Varices Study</brief_title>
	<detailed_description>Gastroesophageal variceal bleed one major complication cirrhosis occur rate 5 15 % per year . 50 % patient cirrhosis develop variceal bleeding lifetime . Large varix size , presence red wale sign endoscopy , decompensated cirrhosis predictor variceal hemorrhage . Current first-line management acute variceal bleed include combination vasoactive drug , endoscopic therapy antibiotic prophylaxis . Despite advance management acute variceal bleeding , 6-week mortality remain significant 15 - 20 % per episode variceal bleeding . In patient survive acute variceal bleed episode without secondary prophylaxis , median rebleeding rate 60 % within 1- 2 year index bleed mortality 33 % . The presence hepatocellular carcinoma ( HCC ) and/or portal vein thrombosis ( PVT ) associate recurrent variceal bleed bad outcome . In retrospective study 2928 HCC patient Hong Kong , 7.9 % patient develop least 1 episode variceal bleed course HCC . In cirrhotic patient PVT without HCC , variceal bleeding uncommon complication . In patient portal hypertension cirrhosis , current guideline recommend non-selective beta-blocker , endoscopic band ligation esophageal varix initial bleeding , either cyanoacrylate injection variceal obturation transjugular intrahepatic portosystemic shunt gastric varix initial bleeding . However , unclear whether strategy clinical effect patient liver cancer and/or portal vein thrombosis high risk recurrent bleeding . Recently , technique endoscopic ultrasound ( EUS ) guide cyanoacrylate ( glue ) injection variceal obturation describe . In study patient gastric variceal bleeding , EUS guide glue injection coil report achieve hemostasis patient 96 % gastric varix remain obliterated follow-up period . To date , dedicate study evaluate role EUS guide glue injection prevention future bleed patient high risk recurrent variceal bleed liver cancer portal vein thrombosis . The investigator propose study evaluate feasibility safety EUS guide glue injection follow-up variceal treatment patient high risk recurrent variceal bleeding , liver cancer and/or portal vein thrombosis .</detailed_description>
	<criteria>Consecutive patient hepatocellular carcinoma ( liver cancer ) , and/or portal vein thrombosis , present gastroesophageal variceal bleed within 12 week Age &gt; 18 year Written inform consent available Contraindications endoscopy due comorbidities Unable provide write informed consent Refractory coagulopathy ( INR &gt; 1.5 ) refractory thrombocytopenia ( platelet &lt; 50,000 ) despite blood product transfusion Pregnant patient Moribund patient terminal illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>